New York, Jan 10, 2026, 21:40 (ET) — Market closed.
- TG Therapeutics shares last closed down 6.6% at $28.47 on Friday.
- CEO Michael S. Weiss received 622,000 restricted shares in a performance award, a filing showed.
- Investors eye the J.P. Morgan Healthcare Conference agenda slot on Tuesday.
TG Therapeutics shares fell 6.6% on Friday to close at $28.47, down $2.03, as the biotech stock swung between $28.21 and $30.83 on about 3.3 million shares.
The drop leaves traders heading into a big week for healthcare stocks as the J.P. Morgan Healthcare Conference opens Monday in San Francisco. “We have seen deals get approved that could have had more regulatory risk in the past,” JPMorgan banker Jeremy Meilman said in a Reuters report on the gathering. (Reuters)
TG Therapeutics sells Briumvi, an anti-CD20 antibody approved in the United States for relapsing forms of multiple sclerosis. With one marketed drug, updates on demand and insurance coverage tend to matter more than broad biotech chatter.
A Form 4 filed on Friday showed chairman and CEO Michael S. Weiss received 622,000 restricted shares in a transaction dated Jan. 8, at a price of $0, lifting his reported holdings to 9,778,086 shares. (OTC Markets)
The filing said the award vests only if TG’s total shareholder return — stock gains plus dividends — beats the Nasdaq Biotechnology Index over multi-year measurement periods. That structure can put more weight on what management says about the next year, even when the award itself is long-dated.
TG Therapeutics is listed on the J.P. Morgan conference agenda for 1:30 p.m. Pacific time on Tuesday (4:30 p.m. ET).
On the product side, Briumvi competes in a crowded multiple sclerosis market that includes Roche’s Ocrevus and Novartis’ Kesimpta. (Roche)
In the next session, traders will look for whether Friday’s selloff draws follow-through selling or bargain hunting, especially if conference headlines pull money toward bigger pharma and away from single-product biotech names.
The risk is straightforward: if Briumvi uptake slows, if payers tighten access, or if rivals sharpen their pitch, TG’s revenue story can flatten quickly — and the stock tends to reprice fast when that happens.
A second date sits on the calendar after JPM: Nasdaq lists TG Therapeutics’ next earnings announcement as estimated for March 2. The nearer catalyst is Tuesday’s conference slot, where investors will listen for any fresh signposts on 2026. (Nasdaq)
